Evidence of the economic benefit of clinical pharmacy services: 1996-2000

Pharmacotherapy

Volumn 23, Issue 1, 2003, Pages 113-132

  Schumock, Glen T ^a   Butler, Melissa G ^a   Meek, Patrick D ^b   Vermeulen, Lee C ^b,c   Arondekar, Bhakti V ^a   Bauman, Jerry L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PHARMACY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL PHARMACY; MONITORING; PATIENT EDUCATION;

EID: 0037228090     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.1.113.31910     Document Type: Article

References (86)

1. Bootman LJ, Wertheimer AI, Zaske D, Rowland C. Individualizing gentamicin dosage in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979;168:267-72.
2. Willett MS, Bertch KE, Rich DS, Ereshefsky L. Prospectus on the economic value of clinical pharmacy services. Pharmacotherapy 1989;9:45-56.
3. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services: 1988-1995. Pharmacotherapy 1996;16:1188-1208.
4. Hatoum HT, Catizone C, Hutchinson RA, Purohit A. An eleven-year review of the pharmacy literature: documentation of the value and acceptance of clinical pharmacy. Drug Intell Clin Pharm 1986;20:33-41.
5. Hatoum HT, Akhras K. A 32-year literature review on the value and acceptance of ambulatory care provided by clinical pharmacists. Ann Pharmacother 1993;27:1108-19.
6. Plumridge RJ, Wojnar Horton RE. A review of pharmacoeconomics of pharmaceutical care. Pharmacoeconomics 1998;14:175-89.
7. Carter BL, Malone DC, Billups SJ, et al. Interpreting the findings of the IMPROVE study. Am J Health-Syst Pharm 2001;58:1330-7.
8. Schumock GT. We've been shown the money, and we now know how to spend it. Pharmacotherapy 1999;19:1349-51.
9. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes, 2nd ed. Oxford, UK: Oxford Medical Publications Inc, 1997.
10. Smith DH, Fassett WE, Christensen DB. Washington state CARE project: downstream cost changes associated with the provision of cognitive services by pharmacists. J Am Pharm Assoc (Wash) 1999;39:650-7.
11. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health-Syst Pharm 1997;54:554-8.
12. Harrison DL, Bootman JL, Cox ER. Cost-effectiveness of consultant pharmacists in managing drug related morbidity and mortality at nursing facilities. Am J Health-Syst Pharm 1998;55:1588-94.
13. Lehmann DF, Medicis JJ. A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services. J Clin Pharmacol 1998;38:783-91.
14. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy 1999;19:556-64.
15. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacist staffing, and drug costs in United States hospitals. Pharmacotherapy 1999;19:1354-62.
16. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy 2000;20:609-21.
17. Watanabe T, Ohta M, Murata M, Yamamoto T. Decrease in emergency room or urgent care visits due to management of bronchial asthma inpatients and outpatients with pharmaceutical services. J Clin Pharm Ther 1998;23:303-9.
18. Boyko WL, Yurkowski PJ, Ivey MF, Armitstead JA, Roberts BL. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm 1997;54:1591-5.
19. Bozek PS, Perdue BE, Bar-Din M, Weidle PJ. Effect of pharmacist interventions on medication use and cost in hospitalized patients with or without HIV infection. Am J Health-Syst Pharm 1998;55:1151-5.
20. McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacistinitiated interventions. Arch Intern Med 1999;159:2306-9.
21. Mutnick AH, Sterba KJ, Peroutka JA, Sloan NE, Beltz EA, Sorenson MK. Cost savings and avoidance from clinical interventions. Am J Health-Syst Pharm 1997;54:392-6.
22. Smythe MA, Shah PP, Spiteri TL, Lucarotti RL, Begle RL. Pharmaceutical care in medical progressive care patients. Ann Pharmacother 1998;32:294-9.
23. Stathoulopoulou F, Papastamatiou L, Lapidakis L. Initiation of clinical pharmacy in Greece. Pharm World Sci 1996;18:229-32.
24. Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother 2000;34:567-72.
25. Engles-Horton LL, Skowronski C, Mostashari F, Altice FL. Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colony-stimulating factor therapy. Pharmacotherapy 1999;19:356-62.
26. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother 1999;33:1026-31.
27. Mamdani MM, Racine E, McCreadie S, et al. Clinical and economic effectiveness of an inpatient anticoagulation service. Pharmacotherapy 1999;19:1064-74.
28. Lucas KS. Outcomes evaluation of a pharmacist discharge medication teaching service. Am J Health-Syst Pharm 1998;55:S32-5.
29. Kinky DE, Erush SC, Laskin MS, Gibson GA. Economic impact of a drug information service. Ann Pharmacother 1999;33:11-16.
30. Alderman CP. A prospective analysis of clinical pharmacy interventions on an acute psychiatric inpatient unit. J Clin Pharm Ther 1997;22:27-31.
31. Baldinger SL, Chow MS, Gannon RH, Kelly ET. Cost savings from having a clinical pharmacist work part-time in a medical intensive care unit. Am J Health-Syst Pharm 1997;54:2811-14.
32. Follin SL, Kwong NM. Enhancement of a pharmacy consultation program on a transitional care unit. Am J Health-Syst Pharm 2000;57:1990-3.
33. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
34. Schumock GT, Michaud J, Guenette AJ. Re-engineering: opportunity to advance clinical practice in a community hospital. Am J Health-Syst Pharm 1999;56:1945-9.
35. Steffen WM, Simmer TF, House KL, Savageau JT. Impact and financial results of a 1-month pharmacist intervention study. Pharmacol Ther 1996;21:34-7.
36. Suseno M, Tedeski L, Kent S, Rough S. Impact of documented pharmacists' interventions on patient care and costs. Hosp Pharm 1998;33:676-81.
37. Taylor CT, Church CO, Byrd DC. Documentation of clinical interventions by pharmacy faculty, residents, and students. Ann Pharmacother 2000;34:843-7.
38. White CM, Chow MSS. Cost Impact and clinical benefits of focused rounding in the cardiovascular intensive care unit. Hosp Pharm 1998;33:419-23.
39. Yee DK, Veal JH, Trinh B, Bauer S, Freeman CH. Involvement of HMO-based pharmacists in clinical rounds at contract hospitals. Am J Health-Syst Pharm 1997;54:670-3
40. Ogle BG, McLean WM, Poston JW. The clinical pharmacy services study: a study of clinical services provided by pharmacists in Ontario hospitals. Can J Hosp Pharm 1996;49:S5-25.
41. Van Lent-Evers NE, Mathot RA, Geus WP, Van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: cost-effectiveness analysis. Ther Drug Monit 1999;21:63-73.
42. Fraser GL, Stogsdill P, Dickens JD, Wennberg DE, Smith RP, Prato BS. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med 1997;157:1689-94.
43. Martinez MJ, Freire A, Castro I, et al. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion. Pharm World Sci 2000;22:53-8.
44. Lata P, VanCourt B, Larson P. Pharmacist as a member of a hospital case management department. Am J Health-Syst Pharm 2000;57:2202-6.
45. Pilzer JD, Burke TG, Mutnick AH. Drug allergy assessment at a university hospital and clinic. Am J Health-Syst Pharm 1996;53:2970-5.
46. Waddell JA, Solimando DA, Strickland WR, Smith BD, Wray MK. Pharmacy staff interventions in a medical center hematology-oncology service. J Am Pharm Assoc (Wash) 1998;38:451-6.
47. Gentry CA, Greenfield RA, Slater LN, Wack M, Huycke MM. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health-Syst Pharm 2000;57:268-74.
48. Lai LL, Sorkin AL. Cost-benefit analysis of pharmaceutical care in a Medicaid population: from a budgetary perspective. J Managed Care Pharm 1998;4:303-8.
49. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158:1641-7.
50. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL Jr. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol 2000;86:519-23.
51. 2 antagonists. Hosp Pharm 1998;33:1102-4, 1110.
52. Spalek VH, Gong WC. Pharmaceutical care in an integrated health system. J Am Pharm Assoc (Wash) 1999;39:553-7.
53. Jermain DM, Sulak PJ, Woodward BW, Knight AB. Psychopharmacy medication clinic in a managed care women's health setting. Am J Health-Syst Pharm 1997;54:2717-18.
54. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Pharmacotherapy 2000;20:1508-16.
55. Segarra-Newnham M, Siebert WF. Development and outcomes of an ambulatory clinic for Helicobacter pylori treatment. Hosp Pharm 1998;33:205-9.
56. Blakey SA, Hixson-Wallace JA. Clinical and economic effects of pharmacy services in geriatric ambulatory clinic. Pharmacotherapy 2000;20:1198-203.
57. Cowper PA, Weinberger M, Hanlon JT, et al. The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy 1998;18:327-32.
58. Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs medical center. Pharmacotherapy 1998;18:1103-11.
59. Malone DC, Carter BL, Billups SJ, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Pharmacotherapy 2000;20:1149-58.
60. Yanchick J, Moore E. Implementation of a pharmacist run drug therapy monitoring clinic in the primary care setting. Am J Health-Syst Pharm 2000;57(suppl 4):S30-4.
61. Libby EA, Laub JJ. Economic and clinical impact of a pharmacy-based antihypertensive replacement program in primary care. Am J Health-Syst Pharm 1997;54:2079-83.
62. Steinweg KK, Killingsworth RE, Nannini RJ, Spayde J. The impact on a health care system of a program to facilitate selfcare. Mil Med 1998;163:139-44.
63. Beck JK, Dries TJ, Cook EC. Development of an interdisciplinary, telephone-based care program. Am J Health-Syst Pharm 1998;55:453-7.
64. Grace KA, McPherson ML, Burstein AH. Diabetes care and cost of pharmacotherapy versus medical services. Am J Health-Syst Pharm 1998;55:S27-9.
65. Rodgers S, Avery AJ, Meechan D, et al. Controlled trial of pharmacist intervention in general practice: the effect on prescribing costs. Br J Gen Pract 1999;49:717-20.
66. Sorrento TA, Bonanza KC, Salisbury DW. Pharmaceutical services in a capitated geriatric care program. Am J Health-Syst Pharm 1996;53:2848-52.
67. McKee J, Grill F, Cline M, Mease T. Clinical pharmacy services in an intermediate-care facility for the developmentally disabled: five-year retrospective review. Consult Pharm 1999;14:1392-8.
68. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17:1274-85.
69. Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther 1997;19:113-23.
70. Benrimoj SI, Langford JH, Berry G, et al. Economic impact of increased clinical intervention rates in community pharmacy: a randomised trial of the effect of education and a professional allowance. Pharmacoeconomics 2000;18:459-68.
71. Miller LG, Scott DM. Documenting indicators of pharmaceutical care in rural community pharmacies. J Managed Care Pharm 1996;2:659-66.
72. Christensen DB, Holmes G, Fassett WE, et al. Principal findings from the Washington State cognitive services demonstration project. Managed Care Interface 1998;11:60-2, 64.
73. Ernst ME, Chalstrom CV, Currie JD, Sorofman B. Implementation of a community pharmacy-based influenza vaccination program. J Am Pharm Assoc (Wash) 1997;37:570-80.
74. McCombs JS, Liu G, Shi J, et al. The Kaiser Permanente/USC patient consultation study: change in use and cost of health care services. Am J Health-Syst Pharm 1998;55:2485-99.
75. Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Managed Care 1998;4:991-1000.
76. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-56.
77. Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997;157:2089-96.
78. Lee JT, Sanchez LA. Interpretation of cost-effective and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991;48:2622-7.
79. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 1993;15:1121-32.
80. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Health-Syst Pharm 1990;47:533-43.
81. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: cost-benefit analysis. Ther Drug Monit 1990;12:419-26.
82. Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists' clinical services. Am J Health-Syst Pharm 2001;58:569-77.
83. Pickard AS, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother 1999;33:1167-72.
84. George B, Silcock J. Economic evaluation of pharmacy services: fact or fiction? Pharm World Sci 1999;21:147-51.
85. Campbell DT. Foreword. In: Trochim WMK, ed. Research design for program evaluation: the regression discontinuity approach. Newbury Park, CA: Sage, 1984:15-43.
86. Campbell DT, Stanley JC. Experimental and quasiexperimental designs for research. Chicago, IL: Rand McNally & Company, 1966.